Bariatric surgery and cardiometabolic outcomes in insulin-treated T2D patients

  • Alkharaiji M & al.
  • Obes Surg
  • 7 Aug 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In obese patients with insulin-treated type 2 diabetes (T2D), bariatric surgery was associated with significant reductions in non-fatal coronary heart disease (CHD) and peripheral artery disease (PAD), body weight, glycated heamoglobin (HbA1c), blood pressure (BP), and insulin independency during the 10-year follow-up period.
  • No significant reductions were observed with the risk of acute myocardial infarction (AMI), stroke, and heart failure (HF)

Why this matters

  • Findings suggest that bariatric surgery should be considered as a genuine therapeutic option to reduce the risk for cardiovascular (CV) events, HbA1c levels and the long-term microvascular complications of diabetes as well as inducing insulin independence in obese patients with insulin-treated T2D.

Study design

  • Retrospective study included 11,125 patients with T2D using data from The Health Improvement Network (THIN) database.
  • Patients who underwent bariatric surgery (n=131) were compared with propensity-score matched non-bariatric group (n=579).
  • Metabolic outcomes and cardiovascular risk events (AMI, stroke, CHD, HF, and PAD) were compared during a follow -up period of 10-years (9686 person-years).
  • Funding: None disclosed.

Key results

  • After adjustment for confounders, bariatric vs non-bariatric group had significant reductions in the risk for non-fatal CHD (HR, 0.29; 95% CI, 0.16-0.52; P<.001 and pad ci p=".03).</li">
  • At 10-year, bariatric vs non-bariatric group had significant reduction in body weight and body mass index (94.1 ± 20.1 vs 107.6 ± 17.3 kg and 32.9 ± 7.7 vs 38.0 ± 7.1 kg/m2 respectively).
  • Bariatric vs non-bariatric group did not differ in the risk for:
    • AMI (HR, 0.98; P=.94),
    • stroke (HR, 0.87; P=.75) and
    • HF (HR, 0.89; P=.73).
  • Bariatric vs non-bariatric group had favourable effects on:
    • HbA1c: At 6-year point (68.1 ± 16.9 vs 72.8 ± 18.8 mmoL/moL),
    • Systolic BP: 1-year (133 ± 17 vs 137 ± 15 mmHg; P=.07); diastolic BP: 2-year (76 ± 10 vs 79 ± 10 mmHg; P<.05 and>
    • Insulin independence: 10-year (77.5% vs 33.7% of patients; P<.0001>

Limitations

  • Retrospective design.
  • Risk of residual confounding.